The Lung Cancer Research Foundation (LCRF) announces the first recipients of its LCRF Team Science Award on Advancing Therapies Toward Curing EGFR Mutated Lung Cancers. The project, "A novel ...

Regeneron Pharmaceuticals plans to expand its pipeline into radiopharmaceutical therapies through an up to $4.3 billion collaboration with Telix Pharmaceuticals to co-develop and co-commercialize ...

At SMH's Brian D. Jellison Cancer Institute, 75 percent of lung cancers diagnosed in 2025 were caught at their earliest, most ...

A newly released report shows 75% of lung cancers diagnosed through an innovative early detection program at Sarasota ...

A new study suggests that a single blood sample could soon detect multiple cancers, including liver, stomach, and lung cancer ...

Keytruda drug is approved for a wide range of solid tumors and blood cancers, often for cases that are advanced, metastatic ...

Sarasota Memorial Health Care System (SMH) reported that 75% of lung cancers diagnosed through an innovative early detection program at SMH's Brian D. Jellison Cancer Institute in 2025 were found at ...

The Scottish Medicines Consortium has approved osimertinib for adults with unresectable stage III EGFR-mutant NSCLC whose disease has not progressed after platinum-based chemoradiation.

Proceeds from the financing will support the advancement of three first- and best-in-class ADC programs through upcoming key clinical milestones While oncology continues to face substantial and ...

Respiratory and lung cancer risks are not linked to asbestos-free talc exposure. While some data is inconclusive, no ...

Lung01 Phase 2 trial, with support from IDeate-PanTumor01 Phase 1/2 trialIf approved, ifinatamab deruxtecan would be a first-in-class B7-H3 directed DXd antibody drug conjugate for these patients ...

In India, Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.